MedTrace Logo

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

NCT01907802 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2018-08-14

No results posted yet for this study

Summary

This phase I trial studies the side effects and best dose of dabrafenib in treating patients with solid tumors and kidney or liver dysfunction. Dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • BRAF Gene Mutation
  • Hepatic Complication
  • Renal Failure
  • Solid Neoplasm

Interventions

DRUG

Dabrafenib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacogenomic Study

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Sponsors & Collaborators

  • Glaxosmithkline Biologicals S.A.

    collaborator UNKNOWN

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Ramesh Ramanathan · Mayo Clinic Cancer Center LAO

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-23
Primary Completion
2015-12-16
Completion
2015-12-16

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01907802 on ClinicalTrials.gov